Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: A randomised, double-blind, placebocontrolled trial

BMC Women's Health

Volumn 15, Issue 1, 2015, Pages

  Heczko, Piotr B ^a   Tomusiak, Anna ^a   Adamski, Pawel ^b   Jakimiuk, Artur J ^c,d   Stefanski, Grzegorz ^e   Mikolajczyk Cichonska, Aleksandra ^e   Suda Szczurek, Magdalena ^e   Strus, Magdalena ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INSTITUTE OF NATURE CONSERVATION   (Poland)

^c CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^d INSTITUTE OF MOTHER AND CHILD   (Poland)

^e IBSS BIOMED SA   (Poland)

Author keywords

Aerobic vaginitis; Bacterial vaginosis; Lactobacillus; Probiotics

Indexed keywords

METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; AEROBIC VAGINITIS; ARTICLE; BACTERIAL COUNT; BREAST DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HUMAN; LACTOBACILLUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; TREATMENT RESPONSE; VAGINA FLORA; VAGINA PH; VAGINITIS; DIETARY SUPPLEMENT; INTRAVAGINAL DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; POLAND; UTILIZATION; VAGINA; VAGINOSIS, BACTERIAL;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-BACTERIAL AGENTS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; METRONIDAZOLE; MIDDLE AGED; POLAND; PROBIOTICS; VAGINA; VAGINOSIS, BACTERIAL;

EID: 84949293904     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/s12905-015-0246-6     Document Type: Article

References (33)

1. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol. 2007;109(1):114-20.
2. Li J, McCormick J, Bocking A, Reid G. Importance of vaginal microbes in reproductive health. Reprod Sci. 2012;19(3):235-42.
3. Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):355-73.
4. Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol. 2004;104(1):114-9.
5. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):375-90.
6. Tempera G, Furneri PM. Management of aerobic vaginitis. Gynecol Obstet Invest. 2010;70(4):244-9.
7. Oduyebo OO, Anorlu RI, Oqunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev. 2009;3:CD006055.
8. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478-86.
9. Han C, Wu W, Fan A, Wang Y, Zhang H, Chu Z, et al. Diagnostic and therapeutic advancements for aerobic vaginitis. Arch Gynecol Obstet. 2015;291(2):251-7.
10. Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health. 2008;8:3.
11. Marcone V, Rocca G, Lichtner M, Calzolari E. Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. Int J Gynaecol Obstet. 2010;110(3):223-6.
12. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol. 2010;203(2):120.e1-6.
13. Delia A, Morgante G, Rago G, Musacchio MC, Petraglia F, De Leo V. Effectiveness of oral administration of Lactobacillus paracasei subsp. paracasei F19 in association with vaginal suppositories of Lactobacillus acidofilus in the treatment of vaginosis and in the prevention of recurrent vaginitis. Minerva Ginecol. 2006;58(3):227-31.
14. Vujic G, Jajac Knez A, Despot Stefanovic V, Kuzmic Vrbanovic V: Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2013, [Epub ahead of print]
15. Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol. 2001;30(1):49-52.
16. Strus M, Brzychczy-Wloch M, Kochan P, Heczko P. Hydrogen peroxide produced by Lactobacillus species as a regulatory molecule for vaginal microflora. Med Dosw Mikrobiol. 2004;56(1):67-77 [Article in Polish]
17. Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis. 2009;22(1):82-6.
18. Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009;4:CD006289.
19. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 3rd ed. New York: Springer-Verlag, selected chapters; 1996.
20. Cook RL, Redondo-Lopez V, Schmitt C, Meriwether C, Sobel JD. Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol. 1992;30(4):870-7.
21. Blackwell AL, Fox AR, Philips I, Barlow D. Anaerobic vaginosis (nonspecific vaginitis): clinical, microbiological and therapeutic findings. Lancet. 1986;2:1379-82.
22. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29(2):297-301.
23. Srinivasan S, Morgan MT, Liu C, Matsen FA, Hoffman NG, Fiedler TL, et al. More than meets the eye: associations of vaginal bacteria with gram stain morphotypes using molecular phylogenetic analysis. PLoS One. 2013;8(10):e78633.
24. Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2013;19(2):141-60.
25. van de Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H, et al. The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS One. 2014;9(8):e105998.
26. Strus M, Chmielarczyk A, Kochan P, Adamski P, Chelmicki Z, Chelmicki A, et al. Studies on the effects of probiotic Lactobacillus mixture given orally on vaginal and rectal colonization and on parameters of vaginal health in women with intermediate vaginal flora. Eur J Obstet Gynecol Reprod Biol. 2012;163(2):210-5.
27. Tomusiak A, Strus M, Heczko PB. Antibiotic resistance of Gardnerella vaginalis isolated from cases of bacterial vaginosis. Ginekol Pol. 2011;82(12):900-4 [Article in Polish].
28. Austin MN, Beigi RH, Meyn LA, Hillier SL. Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol. 2005;43(9):4492-7.
29. Mayer BT, Srinivasan S, Fiedler TL, Marrazzo JM, Fredricks DN, Schiffer JT. Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis. J Infect Dis. 2015. jiv079.
30. Aroutcheva A, Simoes JA, Shott S, Faro S. The inhibitory effect of clindamycin on Lactobacillus in vitro. Infect Dis Obstet Gynecol. 2001;9(4):239-44.
31. Eriksson K, Larsson PG, Nilsson M, Forsum U. Vaginal retention of locally administered clindamycin. APMIS. 2011;119(6):373-6.
32. Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osemene G, Bruce AW, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006;8(6):1450-4.
33. Schulz KF, Altman DG, Moher D for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Ann Intern Med. 2010;152(11):726-732.